PMID- 37955784
OWN - NLM
STAT- MEDLINE
DCOM- 20231204
LR  - 20231217
IS  - 1568-5608 (Electronic)
IS  - 0925-4692 (Linking)
VI  - 31
IP  - 6
DP  - 2023 Dec
TI  - A mechanistic overview of sulforaphane and its derivatives application in 
      diabetes and its complications.
PG  - 2885-2899
LID - 10.1007/s10787-023-01373-z [doi]
AB  - Sulforaphane (SFN) is a type of phytochemical found in many cruciferous 
      vegetables that has been shown to positively benefit the control of Type 2 
      Diabetes Mellitus (T2DM). The search was done from 2000 until December 2022 using 
      PubMed, Scopus, Web of Sciences, and Google Scholar databases. We included all in 
      vitro, in vivo, and clinical trials. Sulforaphane has been demonstrated to 
      activate the PI(3)K/AKT and AMP-activated protein kinase pathways and the glucose 
      transporter type 4 to increase insulin production and reduce insulin resistance. 
      Interestingly, SFN possesses protective effects against diabetes complications, 
      such as diabetic-induced hepatic damage, vascular inflammation and endothelial 
      dysfunction, nephropathy, and neuropathy via nuclear factor erythroid 2-related 
      factor 2 activation that leads to the translation of several anti-oxidant enzymes 
      and regulation glycolysis, pentose phosphate pathway, fatty acid metabolism, 
      glutamine metabolism, and glutathione metabolism. Furthermore, multiple clinical 
      trial studies emphasized the ameliorating effects of SFN on T2DM patients. This 
      review provides sufficient evidence for further research and development of 
      sulforaphane as a hypoglycemic drug.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
FAU - Mohamadi, Neda
AU  - Mohamadi N
AD  - Herbal and Traditional Medicine Research Center, Kerman University of Medical 
      Sciences, Kerman, Iran.
FAU - Baradaran Rahimi, Vafa
AU  - Baradaran Rahimi V
AD  - Department of Cardiovascular Diseases, Faculty of Medicine, Mashhad University of 
      Medical Sciences, Mashhad, Iran.
FAU - Fadaei, Mohammad Reza
AU  - Fadaei MR
AD  - Department of Pharmaceutics, School of Pharmacy, Mashhad University of Medical 
      Sciences, Mashhad, Iran.
FAU - Sharifi, Fatemeh
AU  - Sharifi F
AD  - Research Center of Tropical and Infectious Diseases, Kerman University of Medical 
      Sciences, Kerman, Iran. fatemeh7267@gmail.com.
FAU - Askari, Vahid Reza
AU  - Askari VR
AUID- ORCID: 0000-0001-9268-6270
AD  - Pharmacological Research Center of Medicinal Plants, Mashhad University of 
      Medical Sciences, Mashhad, Iran. askariv@mums.ac.ir.
AD  - Applied Biomedical Research Center, Mashhad University of Medical Sciences, 
      Mashhad, Iran. askariv@mums.ac.ir.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231113
PL  - Switzerland
TA  - Inflammopharmacology
JT  - Inflammopharmacology
JID - 9112626
RN  - GA49J4310U (sulforaphane)
RN  - 0 (Antioxidants)
RN  - 0 (Isothiocyanates)
RN  - 0 (NF-E2-Related Factor 2)
SB  - IM
MH  - Animals
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/drug therapy/metabolism
MH  - *Diabetes Mellitus, Experimental/drug therapy
MH  - Antioxidants/pharmacology
MH  - Isothiocyanates/pharmacology/therapeutic use
MH  - NF-E2-Related Factor 2/metabolism
MH  - Oxidative Stress
OTO - NOTNLM
OT  - Inflammation
OT  - Insulin
OT  - Oxidative stress
OT  - Peroxisome proliferator-activated receptor-gamma
OT  - Sulforaphane
OT  - Type 2 diabetes
EDAT- 2023/11/13 12:41
MHDA- 2023/12/04 12:42
CRDT- 2023/11/13 11:10
PHST- 2023/07/07 00:00 [received]
PHST- 2023/10/09 00:00 [accepted]
PHST- 2023/12/04 12:42 [medline]
PHST- 2023/11/13 12:41 [pubmed]
PHST- 2023/11/13 11:10 [entrez]
AID - 10.1007/s10787-023-01373-z [pii]
AID - 10.1007/s10787-023-01373-z [doi]
PST - ppublish
SO  - Inflammopharmacology. 2023 Dec;31(6):2885-2899. doi: 10.1007/s10787-023-01373-z. 
      Epub 2023 Nov 13.